


16th EGS Residents' Course

Lisbon

29-30 September 2023





Sophia de Mello

08:40 08:50	Welcome and Introduction Luis Abegão Pinto, Fotis Topouzis
09:00 12:15	SESSION 1 - OPEN AND ANGLE-CLOSURE GLAUCOMAS Moderators: Andrew Tatham, Carlo E. Traverso
09:00	Terminology, treatment principles, individualized treatment David Garway-Heath
09:20	Q&A
09:30	Primary open-angle glaucomas Fotis Topouzis
09:50	Q&A
10:00	Secondary OAG Sanna Leinonen
10:20	Q&A
10:30 10:45	Coffee break
	Moderators: Luis Abegão Pinto, Ingeborg Stalmans
10:45	Primary and secondary ACG João Barbosa Breda
11:05	Q&A
11:15	Congenital / Juvenile glaucoma Stylianos Georgoulas
11:35	Q&A
11:45	Discussion
12:15 13:15	Lunch



Sophia de Mello

13:15 16:00	SESSION 2 - MEDICAL AND SURGICAL THERAPY OF GLAUCOMA Moderators: Alain Bron, Gordana Sunaric Megevand
13:15	General principles of glaucoma - treatment & target Marta Pazos
13:25	Q&A
13:35	Anti-glaucoma drugs Gerhard Garhöfer
13:55	Q&A
14:05	Laser in glaucoma Anthony Khawaja
14:15	Q&A
14:25	Cataract surgery in glaucoma Carlo E. Traverso
14:35	Q&A
14:45	Trabs and tubes Andrew Tatham
15:05	Q&A
15:15	Newer glaucoma surgeries Karl Mercieca
15:35	Q&A
15:45	Discussion
16:00 16:15	Coffee break



Sophia de Mello

16:15 17:15	SESSION 3 – RANDOMIZED TRIALS AND ECONOMICS Moderators: Theodoros Filippopoulos, Sophie Lemmens
16:15	Randomized controlled trials David Garway-Heath
16:35	Q&A
16:45	Cost-effectiveness of glaucoma care Gauti Johannesson
17:05	Q&A
17:15 17:20	Discussion and closing remarks



Sophia de Mello

08:45 09:00 **SESSION 4 - "THE WAKE UP SESSION" QUIZ**

Contest and prize delivery

Quiz: - Sanna Leinonen, Luis Abegão Pinto

Prize: Gauti Johannesson

WORKSHOPS

Sophia de Mello

09.10-10.10 / 10.30-11.30 / 11.30-12.30

WORKSHOP 1: OPTIC DISC

Panelists: David Garway-Heath, Sanna Leinonen, Karl Mercieca, Stylianos Georgoulas, Anthony Khawaja

Amalia Rodrigues

09.10-10.10 / 10.30-11.30 / 11.30-12.30

WORKSHOP 2: OCT

Panelists: Marta Pazos, Gauti Johannesson, Ilgaz Yalvac,
Theodoros Filippopoulos, Sophie Lemmens, Rafael Correia Barão

Lopez Graça

09.10-10.10 / 10.30-11.30 / 11.30-12.30

WORKSHOP 3: PERIMETRY

Panelists: Ananth Viswanathan, Luis Abegão Pinto, João Barbosa Breda, Efthymios Karmiris, Giovanni Montesano

10:10 10:30 Coffee break

12:30

Lunch

14:00



WORKSHOPS

Sophia de Mello

14:00 - 15:00 / 15:00 - 16:00 / 16:20 - 17:20 WORKSHOP 4: GONIOSCOPY

Panelists: Anton Hommer, Sophie Lemmens, Carlo Cutolo

Amalia Rodrigues

14:00 - 15:00 / 15:00 - 16:00 / 16:20 - 17:20 **WORKSHOP 5: CLINICAL MANAGEMENT**

Panelists: Gordana Sunaric Mégevand, Alain Bron, Efthymios Karmiris, Dorothea Peters

Lopez Graça

14.00 - 15.00/15.00 - 16.00/ 16.20 - 17.20 **WORKSHOP 6: SURGERY (MICROSCOPES)**

Panelists: Luis Abegão Pinto, Ingeborg Stalmans, Rafael Correia Barão, Andrew Tatham, Karl Mercieca

16:00 16:20 Coffee break



16th EGS Residents' Course

Solve 16th EGS Residents' Course

29-30 September 2023

ACKNOWLEDGEMENTS

The European Glaucoma Society is grateful to the Educational Partners for their long-standing commitment

Alcon





Alcon

We Help People See Brilliantly.

At Alcon, we aspire to lead the world in innovating life-changing vision products because when people see brilliantly, they live brilliantly.

Each year our products touch the lives of millions of people living with conditions like cataracts, glaucoma, retinal diseases, and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as a differentiated portfolio of contact lenses, lens care solutions, and pharmaceutical and over-the-counter eye drops. Alcon is also at the forefront of innovation, partnering with Eye Care Professionals to bring the gift of sight to more people around the world.

That's been our legacy for more than 75 years—and continues to guide our focus towards the brilliant future ahead.

Learn more at alcon.com

CONNECT WITH US!



@AlconEyeCare @AlconCareers



@Alcon



@AlconLife



@Alcon

© 2022 Alcon Inc. 07/22 2207N1238



CHALLENGING THE STATUS QUO IN GLAUCOMA WITH YOU



We know that as ophthalmologists you work tirelessly to transform the lives of people with glaucoma. Faced with issues such as treatment adherence, caused by a range of factors including ocular surface disease,¹ ophthalmologists work with medical treatment options that have stayed broadly the same for 25 years.^{2,3}

It's time for a change.

For over a century, Santen has been committed to protecting the precious sense of sight. In pursuit of better eye health for all, our mission is to build a portfolio that supports ophthalmologists in meeting the diverse needs of their patients.

Stay tuned to know more.

1. Kaštelan S, Tomi M, Metež Soldo K, Salopek-Rabati J. How ocular surface disease impacts the glaucoma treatment outcome. *Biomed Res Int.* 2013;2013:696328. doi:10.1155/2013/696328. Z. Santen. Santen confirmed as Marketing Authorisation Holder of Rhoklinsa® and Roclanda® in the EEA and UK after transfer from Aerie Pharmaceuticals. Available at: https://www.santen.eu/our-vision/media/santen-confirmed-marketing-authorisation-holder-rhoklinsa-and-roclanda (Accessed May 2022). 3. Glaucoma Research Foundation. 'Glaucoma Facts and Stats'. Available at: https://glaucoma.org/glaucoma-facts-and-stats/ (Accessed May 2022).



Théa is a company with deeply European roots, whose independence, stability, and entrepreneurial spirit are guaranteed by the Chibret family, who have been leaving their mark on the world of ophthalmology for the last 150 years.

Being a family-owned business has allowed Théa to

Being a family-owned business has allowed Théa to develop over the long-term, focusing on employees and human values to accomplish our mission of being the "Ophthalmology Specialist". A pioneer in preservative-free treatments, we are committed to providing healthcare professionals and patients with innovative products and a wide range of speciality items (service products, daily-use products) across all ophthalmological therapeutic categories.

We are continually reinvesting in our two main areas of interest, Innovation and Internationalisation, with long-term strategy being favoured over short-term profits.

Our goal is to pursue and strengthen long-term partnerships and collaborative research, to share our expertise and address unmet medical needs to provide new methods for treating and supporting patients. Internationalisation is in our genes: currently the top independent pharmaceutical company in Europe, Théa has set its sights on becoming a world leader by continuing to export its products and establish itself internationally, while always respecting the cultures of each country.

This vision is what makes Théa unique.

let's open our eyes

LABORATOIRES-THEA.COM